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Abstract 3,4-Methylenedioxymethamphetamine (MDMA,
‘‘ecstasy’’) popular as a designer drug is often used with caf-
feine to gain a stronger stimulant effect. MDMA induces 5-HT
and DA release by interaction with monoamine transporters.
Co-administration of caffeine and MDMA may aggravate
MDMA-induced toxic effects on DA and 5-HT terminals. In
the present study, we determined whether caffeine influences
DA and 5-HT release induced by MDMA. We also tried to find
out if adenosine A1 and A2A receptors play a role in the effect
of caffeine by investigating the effect of the selective adeno-
sine A1 and A2A receptor antagonists, DPCPX and KW 6002
on DA and 5-HT release induced by MDMA. Mice were
treated with caffeine (10 mg/kg) and MDMA (20 or 40 mg/
kg) alone or in combination. DA and 5-HT release in the mouse
striatum was measured using in vivo microdialysis. Caffeine
exacerbated the effect of MDMA on DA and 5-HT release.
DPCPX or KW 6002 co-administered with MDMA had sim-
ilar influence as caffeine, but KW 6002 was more potent than
caffeine or DPCPX. To exclude the contribution of MAO
inhibition by caffeine in the caffeine effect on MDMA-induced
increase in DA and 5-HT, we also tested the effect of the
nonxanthine adenosine receptor antagonist CGS 15943A
lacking properties of MAO activity modification. Our findings
indicate that adenosine A1 and A2A receptor blockade may
account for the caffeine-induced exacerbation of the MDMA
effect on DA and 5-HT release and may aggravate MDMA
toxicity.




is a designer drug structurally related to the hallucinogenic
mescaline and amphetamine. Its illicit use by ‘‘rave’’ party
participants is a serious social problem. In addition, it
induces neurotoxicity observed in experimental models and
in humans. The data obtained in laboratory animals in vivo
have revealed that MDMA interacts with monoamine
transporters to stimulate non-exocytotic release of seroto-
nin (5-HT), dopamine (DA), and noradrenaline (NA)
(Baumann et al. 2005; Gudelsky and Nash 1996; Sulzer
et al. 2005; Yamamoto and Spanos 1988). MDMA has
mood-enhancing properties and hallucinogenic effects in
humans (Sulzer et al. 2005). Its acute peripheral symptoms
include hyperthermia, increased blood pressure, tachycar-
dia, acute renal and liver failure, convulsions, and cerebral
hemorrhage resulting in death (Capela et al. 2009). A long-
term MDMA intake causes neurotoxic effects to the sero-
tonergic fibers in the forebrain leaving raphe cell bodies
unaffected (Xie et al. 2006) as observed in rats and non-
human primates (Capela et al. 2009). A wide variety of
abused drugs are often found in ecstasy tablets to gain a
stronger stimulant effect and such combinations of MDMA
with other compounds may be extremely toxic leading to
enhanced adverse effects. For instance, high amount of
caffeine has been often detected in ecstasy tablets. Indi-
viduals exposed to excessive doses of caffeine presented
anxiety, agitation, hallucinations, convulsions, and mim-
icking the effects of stimulant recreational drugs (Davies
et al. 2012). The primary action of caffeine is to block
adenosine A1 and A2A receptors which leads to secondary
effects on many classes of neurotransmitters (Fredholm
et al. 1999). Inhibitory adenosine A1 receptors are present
in almost all brain areas and their stimulation can suppress
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neuronal excitability (Fredholm et al. 1994). Adenosine
A2A receptors concentrated in the dopamine rich areas of
the brain activate adenylyl cyclase and some types of
voltage-sensitive Ca2?-channels (Fredholm et al. 1994).
Thus, adenosine A1 and A2A receptors have opposing
actions at cellular and neuronal levels. The central stimu-
latory effect of caffeine seems to be related with the
blockade of adenosine A1 receptors causing increases of
5-HT, DA and NA turnover (Hadfield and Milio 1989),
elevation of DA level in the striatum (Morgan and Vestal
1989). In addition, an A1 antagonist was shown to enhance
locomotion in rodents (Popoli et al. 1996). A2A receptors
are abundant in the striatum and nucleus accumbens where
they are expressed on the GABAergic neurons or are
present on glutamatergic neuronal terminals thus control-
ling the basal ganglia output and input neurons (Sven-
ningsson et al. 1998). There is evidence that A2A receptors
oppose the effects of dopamine D2 receptors (Ferre´ et al.
1997). Thus, an inhibition of A2A receptors by caffeine can
increase rotation behavior induced by dopamine agonists
(Fenu et al. 1997), while dopamine receptor antagonists can
inhibit the stimulatory effects of caffeine on locomotion
(Garret and Holtzman 1994). Caffeine co-administered with
MDMA potentiated the MDMA effect on extracellular DA
level in the striatum of anesthetized rats (Ikeda et al. 2011)
and enhanced MDMA-induced DA release from the rat
striatal slices and this effect was suggested to be mediated via
adenosine A1 receptors (Vanattou-Saı¨foudine et al. 2011).
On the other hand, exacerbation of MDMA-induced hyper-
thermia by caffeine is proposed to result from the inhibition
of adenosine A2A receptors (Vanattou-Saı¨foudine et al.
2010). Hyperthermia and neuroinflammation after acute but
not chronic administration of caffeine and MDMA have been
reported to cause neurotoxic effects in rodents (Khairnar
et al. 2010; McNamara et al. 2006; Ruiz-Medina et al. 2013;
Vanattou-Saı¨foudine et al. 2011). In contrast to rats and non-
human primates, MDMA produces rather dopaminergic
neurotoxicity in mice (Colado et al. 2001). However,
depending on MDMA dosage and mouse strain, it can cause
5-HT neurotoxicity, as well (Fornai et al. 2004). According
to the hypothesis of Sprague et al. (1998), acute doses of
MDMA induce 5-HT and DA release. 5-HT released by
MDMA decreases inhibitory GABAergic transmission via
5-HT2A/C receptors situated on GABA interneurons, this
effect is followed by increased DA release. The excessive
DA transported into serotonergic terminals may be metab-
olized through MAO-B into 3,4-dihydroxyphenylacetic acid
(DOPAC) and hydrogen peroxide which would result in free
radical generation. Thus, either DA or 5-HT may be a
determinant of MDMA neurotoxicity. Co-administration of
caffeine and MDMA may aggravate MDMA-induced toxic
effects on DA and 5-HT terminals via the mechanism
engaging adenosine A1/A2A receptors. To date, there are no
data about in vivo effects of caffeine and MDMA co-
administration in mice. Therefore, in our study, we were
interested in investigating whether acute treatment with
caffeine affects MDMA-induced release of DA and 5-HT in
the mouse striatum using in vivo microdialysis. In addition,
we attempted to explain the specific role of adenosine A1 and
A2A receptors in the caffeine effect by investigating the
influence of selective adenosine A1 and A2A receptor
antagonists, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX),
and (E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-
dihydro-1H-purine-2,6-dione (KW 6002) on the MDMA-
induced DA and 5-HT release. To exclude the contribution of
MAO inhibition by caffeine in the caffeine effect on
MDMA-induced increase in DA and 5-HT, we also tested the
effect of the nonxanthine adenosine receptor antagonist CGS
15943A lacking properties of MAO activity modification.
Materials and Methods
Animals
Experiments were performed on adult male (8–10 weeks
old) C57BL/6J inbred mice. The animals were housed 5–7
per cage, under a 12-h light/12-h dark cycle, with free
access to standard food and tap water. The experiments
were conducted in accordance with the European Union
guidelines regarding the care and use of laboratory animals
(Council Directive 86/609/EEC of November 24, 1986)




and CGS 15943A (9-chloro-2-(2-furyl)[1,2,4]triazolo[1,5-
c]quinazoline-5-amine) were obtained from Sigma-Aldrich
(Poznan´, Poland), while KW 6002 [(E)-1,3-diethyl-8-(3,4-
dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione]
was purchased from Selleckchem (USA). Caffeine was
dissolved in 0.9 % NaCl, while DPCPX and KW 6002
were dissolved initially in dimethyl sulfoxide (DMSO) and
were then suspended in 0.3 % Tween 80. All injections
were done with intraperitoneal route and control animals
received respective vehicles. The chemicals used for HPLC
were purchased from Merck (Warsaw, Poland).
Brain Microdialysis
Animals were anesthetized with ketamine (7.5 mg/kg) and
xylazine (1 mg/kg), and a vertical microdialysis probes
were implanted into the striatum using the following
coordinates: AP ? 1.0, L ? 1.8, V - 3.8 (Paxinos and
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Franklin 2001). On the next day, probe inlets were con-
nected to a syringe pump (BAS, IN, USA) which delivered
a CSF composed of [mM]: NaCl 147, KCl 2.7, MgCl2 1.0,
CaCl2 1.2; pH 7.4 at a flow rate of 1.5 ll/min. After 1 h of
the washout period, three basal dialysate samples were
collected every 30 min; then animals were injected with
appropriate drugs in doses indicated in figure captions and
fraction collection continued for 270 min. At the end of the
experiment, the mice were sacrificed and their brains were
histologically examined to validate the probe placement.
Analytical Procedure
DA, 5-HT, 3-MT, 3,4-dihydroxyphenylacetic acid (DOPAC),
homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-
HIAA) were analyzed by high-performance liquid chroma-
tography (HPLC) with coulochemical detection. Chroma-
tography was performed using an Ultimate 3000 System
(Dionex, USA), coulochemical detector Coulochem III
(model 5300, ESA, USA) with 5020 guard cell, 5014B
microdialysis cell and Hypersil Gold C18 analytical column
(3 9 100 mm). The mobile phase was composed of 0.1 M
potassium phosphate buffer adjusted to pH 3.6, 0.5 mM
EDTA, 16 mg/L 1-octanesulfonic acid sodium salt, and 2 %
methanol. The flow rate during analysis was set at 0.7 ml/min.
The applied potential of a guard cell was ?600 mV, while
those of microdialysis cells were: E1 = -50 mV,
E2 = ?300 mV with a sensitivity set at 50 nA/V. The chro-
matographic data were processed by Chromeleon v. 6.80
(Dionex, USA) software run on a PC computer.
Data Analysis
All obtained data were presented as a percent of the basal
level assumed as 100 %. The statistical significance was
calculated using a repeated measures ANOVA or where
appropriate a one-way ANOVA, followed by Tukey’s post-
hoc test. The results were considered statistically signifi-
cant when P \ 0.05.
Results
The Effect of Caffeine and Adenosine A1 and A2A
Receptor Antagonists DPCPX and KW 6002 on DA
Release Induced by MDMA in the Striatum
of the Mouse
MDMA at doses of 20 and 40 mg/kg significantly
(P = 0.0001) increased DA release by ca. 560 and 1,400 %
of the basal level at 60 min after administration. Caffeine at
a dose of 10 mg/kg, but not at a dose of 5 mg/kg (results not
shown) markedly enhanced the effect of MDMA on DA
release given at a dose of 40 mg/kg (P = 0.0002); however,
it did not affect significantly the increase in DA release
produced by MDMA in a lower dose of 20 mg/kg (Fig. 1a,
b). Repeated measures ANOVA of these data showed a
statistically significant effect of treatment groups
[F5,28 = 262, P = 0], sampling period [F8,224 = 312,
P = 0], and the interaction between treatment groups and
sampling period [F40,224 = 122, P = 0].
The selective adenosine A1 receptor antagonist DPCPX
at a dose of 2.5 mg/kg but not at a dose of 1.25 mg/kg
significantly (P = 0.0001) enhanced the effect of MDMA
(40 mg/kg) on DA release (Fig. 1c). Repeated measures
ANOVA showed a significant effect of treatment groups
[F5,26 = 445, P = 0], sampling period [F8,208 = 245,
P = 0], and the interaction between treatment groups and
sampling period [F40,208 = 62, P = 0].
The selective adenosine A2A receptor antagonist KW
6002 at both doses of 1.25 and 2.5 mg/kg significantly
(P = 0.0001) increased the effect of MDMA (40 mg/kg) on
DA release (Fig. 1d). Repeated measures ANOVA showed a
significant effect of treatment groups [F5,28 = 627, P = 0],
sampling period [F8,224 = 194, P = 0], and the interaction
between treatment groups and sampling period [F40,225 =
78, P = 0].
The basal extracellular DA level in dialysate fractions
from the mouse striatum was 7.74 ± 0.71 (pg/10 ll,
n = 103) and no significant differences between experi-
mental groups were observed.
The Effect of Caffeine and Adenosine A1 and A2A
Receptor Antagonists DPCPX and KW 6002 on 5-HT
Release Induced by MDMA in the Striatum
of the Mouse
MDMA at doses of 20 and 40 mg/kg significantly
(P = 0.0001) increased 5-HT release in the mouse striatum
by ca. 389 and 510 % of the basal level at 60 min after
administration. Caffeine (10 mg/kg), but not at a dose of
5 mg/kg (results not shown) significantly increased the
effect of both MDMA doses (20 and 40 mg/kg) on 5-HT
release (P = 0.002 and P = 0.0001, respectively) (Fig. 2a,
b). Repeated measures ANOVA showed a significant effect
of treatment groups [F5,26 = 372, P = 0], sampling period
[F8,208 = 101, P = 0], and the interaction between treat-
ment groups and sampling period [F40,208 = 15, P = 0].
A selective adenosine A1 receptor antagonist DPCPX at
a dose of 2.5 mg/kg but not 1.25 mg/kg significantly
(P = 0.0001) enhanced the effect of MDMA (40 mg/kg)
on 5-HT release (Fig. 2c). Repeated measures ANOVA
showed a significant effect of treatment groups [F5,23 =
618, P = 0], sampling period [F8,184 = 80, P = 0], and
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Fig. 1 The effect of caffeine
(CAF) and adenosine A1 and
A2A receptor antagonists,
DPCPX and KW 6002 (KW) on
DA release induced by MDMA
in the mouse striatum. CAF
(10 mg/kg), DPCPX (1.25 and
2.5 mg/kg), and KW (1.25 and
2.5 mg/kg) were injected
simultaneously with MDMA 20
or 40 mg/kg as indicated with
an arrow. Values are the
mean ± SEM (n = 6–8
animals). *P \ 0.0001
represents a significant
difference in comparison to
control group; ‘‘a’’ P \ 0.0002
represents a significant
difference in comparison to
MDMA group (repeated
measures ANOVA and Tukey’s
post-hoc test)
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Fig. 2 The effect of caffeine
(CAF) and adenosine A1 and
A2A receptor antagonists,
DPCPX and KW 6002 (KW) on
5-HT release induced by
MDMA in the mouse striatum.
CAF (10 mg/kg), DPCPX (1.25
and 2.5 mg/kg), and KW (1.25
and 2.5 mg/kg) were injected
simultaneously with MDMA 20
or 40 mg/kg as indicated with
an arrow. Values are the
mean ± SEM (n = 6–8
animals). *P \ 0.0001
represents a significant
difference in comparison to
control group; ‘‘a’’
P \ 0.0002–0.01 represents a
significant difference in
comparison to MDMA group
(repeated measures ANOVA
and Tukey’s post-hoc test)
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the interaction between treatment groups and sampling
period [F40,184 = 45, P = 0].
The selective adenosine A2A receptor antagonist KW
6002 at both doses of 1.25 and 2.5 mg/kg significantly
(P = 0.0001) increased the effect of MDMA (40 mg/kg)
on 5-HT release (Fig. 2d). Repeated measures ANOVA
showed a significant effect of treatment groups
[F5,26 = 236, P = 0], sampling period [F8,208 = 80,
P = 0], and the interaction between treatment groups and
sampling period [F40,208 = 34, P = 0]. The basal extra-
cellular 5-HT level in dialysates from the mouse striatum
was 2.30 ± 0.13 (pg/10 ll, n = 99) and no significant
differences between experimental groups were observed.
The Effect of Caffeine and Adenosine A1 and A2A
Receptor Antagonists DPCPX and KW 6002
on MDMA-Induced Changes in Extracellular 3-MT
Level in the Striatum of the Mouse
The level of the extraneuronal DA metabolite, 3-MT was
significantly (P = 0.0001) increased by MDMA 20 and
40 mg/kg to ca. 711 and 1736 % of the basal values,
respectively, between 60 and 120 min after administration.
Caffeine (10 mg/kg) significantly (P = 0.0002) increased
the effect of a higher dose (40 mg/kg) of MDMA on 3-MT
extracellular level, but did not affect the increase in 3-MT
induced by a lower dose of MDMA (Fig. 3a, b). Repeated
measures ANOVA showed a significant effect of treatment
groups [F5,25 = 274, P = 0], sampling period
[F8,200 = 233, P = 0], and the interaction between treat-
ment groups and sampling period [F40,200 = 57, P = 0].
The selective adenosine A1 receptor antagonist DPCPX
at both doses, 1.25 and 2.5 mg/kg significantly
(P = 0.0001 and P = 0.01, respectively) increased the
effect of MDMA (40 mg/kg) on extracellular 3-MT level
(Fig. 3c). Repeated measures ANOVA showed a signifi-
cant effect of treatment groups [F5,24 = 388, P = 0],
sampling period [F8,192 = 433, P = 0], and the interaction
between treatment groups and sampling period [F40,192 =
137, P = 0].
The selective adenosine A2A receptor antagonist KW
6002 at both doses 1.25 and 2.5 mg/kg significantly
(P = 0.0001) increased the effect of MDMA (40 mg/kg)
on extracellular 3-MT level (Fig. 3d). Repeated measures
ANOVA showed a significant effect of treatment groups
[F5,28 = 556, P = 0], sampling period [F8,224 = 215,
P = 0], and the interaction between treatment groups
and sampling period [F40,224 = 61, P = 0]. The basal
extracellular 3-MT level in dialysates from the mouse
striatum was 14.15 ± 0.95 (pg/10 ll, n = 102) and no
significant differences between experimental groups were
observed.
The Effect of Caffeine and Adenosine A1 and A2A
Receptor Antagonists DPCPX and KW 6002
on MDMA-Induced Changes in Extracellular Level
of DOPAC, HVA, and 5-HIAA in the Striatum
of the Mouse
MDMA at doses of 20 and 40 mg/kg significantly
(P = 0.0001) decreased the level of the intraneuronal
metabolite of DA, DOPAC to ca. 14 and 9 % of basal level at
120 min after administration. Caffeine at a dose of 10 mg/kg
had no effect on the decrease in DOPAC level induced by both
doses of MDMA (Fig. 4a). Repeated measures ANOVA of
these data showed a statistically significant effect of treatment
groups [F5,29 = 123, P = 0], sampling period [F8,232 = 80,
P = 0], and the interaction between treatment groups and
sampling period [F40,232 = 9.7, P = 0].
The selective adenosine A1 receptor antagonist DPCPX
at both doses, 1.25 and 2.5 mg/kg did not affect the
decrease in extracellular DOPAC level produced by
MDMA 40 mg/kg (Fig. 5a). Repeated measures ANOVA
of these data showed a statistically significant effect of
treatment groups [F3,15 = 77, P = 0], sampling period
[F8,120 = 78, P = 0], and the interaction between treat-
ment groups and sampling period [F24,120 = 10.1, P = 0].
Similarly, the selective adenosine A2A receptor antagonist
KW 6002 at both doses 1.25 and 2.5 mg/kg also did not
influence the extracellular level of DOPAC decreased by
MDMA (Fig. 5b). Repeated measures ANOVA of these
data showed a statistically significant effect of treatment
groups [F3,19 = 77, P = 0], sampling period [F8,152 = 89,
P = 0], and the interaction between treatment groups and
sampling period [F24,152 = 8.78, P = 0].
The extracellular level of HVA was significantly decreased
by MDMA 20 and 40 mg/kg (P = 0.004 and 0.0002,
respectively, in comparison to control group). Caffeine
(10 mg/kg) did not change the effect of both doses of MDMA
on the extracellular HVA level (Fig. 4b). Repeated measures
ANOVA of these data showed a statistically significant effect
of treatment groups [F5,28 = 11.2, P = 0.0001], sampling
period [F8,224 = 17.7, P = 0], and the interaction between
treatment groups and sampling period [F40,224 = 5.30,
P = 0].
The adenosine A1 receptor antagonist DPCPX at doses
of 1.25 and 2.5 mg/kg was without influence on the
extracellular level of HVA decreased by MDMA (40 mg/
kg) (Fig. 5c). Repeated measures ANOVA of these data
showed a statistically significant effect of treatment groups
[F3,15 = 12.2, P = 0.003], sampling period [F8,120 = 31,
P = 0], and the interaction between treatment groups and
sampling period [F24,120 = 3.64, P = 0.0001]. Similarly,
the selective adenosine A2A receptor antagonist KW 6002
at both doses 1.25 and 2.5 mg/kg also did not influence
extracellular level of HVA decreased by MDMA (Fig. 5d).
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Fig. 3 The effect of caffeine
(CAF) and adenosine A1 and
A2A receptor antagonists,
DPCPX and KW 6002 (KW) on
extracellular level of 3-MT
increased by MDMA in the
mouse striatum. CAF (10 mg/
kg), DPCPX (1.25 and 2.5 mg/
kg), and KW (1.25 and 2.5 mg/
kg) were injected
simultaneously with MDMA 20
or 40 mg/kg as indicated with
an arrow. Values are the
mean ± SEM (n = 6–8
animals). *P \ 0.0001
represents a significant
difference in comparison to
control group; ‘‘a’’ P \ 0.0002
represents a significant
difference in comparison to
MDMA group (repeated
measures ANOVA and Tukey’s
post-hoc test)
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Repeated measures ANOVA of these data showed a sta-
tistically significant effect of treatment groups
[F3,19 = 7.37, P = 0.002], sampling period [F8,152 = 5.7,
P = 0.0001], and the interaction between treatment groups
and sampling period [F24,152 = 2.19, P = 0.002].
MDMA in a dose of 40 mg/kg but not in the lower one
20 mg/kg significantly decreased extracellular level of
serotonin metabolite, 5-HIAA (P = 0.008 in comparison
to control group). Caffeine (10 mg/kg) had no effect on
this decrease (Fig. 4c). Repeated measures ANOVA of
these data showed a statistically significant effect of
treatment groups [F5,28 = 5.5, P = 0.001], sampling per-
iod [F8,224 = 7.5, P = 0.0001], and the interaction
between treatment groups and sampling period [F40,224 =
2.54, P = 0.0001].
The adenosine A1 receptor antagonist DPCPX at a dose
of 2.5 mg/kg but not at a lower one (1.25 mg/kg) reversed
the effect of MDMA (40 mg/kg) on the extracellular
5-HIAA level (P = 0.03, Fig. 5c). Repeated measures
ANOVA of these data showed a statistically significant
effect of treatment groups [F3,15 = 15.1, P = 0.0001],
sampling period [F8,120 = 4.34, P = 0.0001], and the
interaction between treatment groups and sampling period
[F24,120 = 3.18, P = 0.0001]. The decrease in extracellular
5-HIAA level produced by MDMA 40 mg/kg was also
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Fig. 4 The effect of caffeine
(CAF) on changes in
extracellular level of DOPAC,
HVA, and 5-HIAA induced by
MDMA in the mouse striatum.
CAF (10 mg/kg) was injected
simultaneously with MDMA 20
or 40 mg/kg as indicated with
an arrow. Values are the
mean ± SEM (n = 6–8
animals). *P \ 0.0001
represents a significant
difference in comparison to
control group (repeated
measures ANOVA and Tukey’s
post-hoc test)
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A2A receptor antagonist KW 6002 (P = 0.0003, Fig. 5f).
Repeated measures ANOVA of these data showed a sta-
tistically significant effect of treatment groups [F3,19 =
6.2, P = 0.004], sampling period [F8,152 = 8.21, P = 0],
but there were no interactions between treatment groups
and sampling period [F24,152 = 1.22, P = 0.24].
The basal extracellular levels of DOPAC, HVA, and
5-HIAA (in pg/10 ll, n = 183) were 1470 ± 148,
1350 ± 166, and 342 ± 30, respectively, and no significant
differences between experimental groups were observed.
The Effect of Caffeine and Adenosine A1 and A2A
Receptor Antagonists DPCPX and KW 6002
on Extracellular Level of DA, 5-HT, 3-MT, DOPAC,
HVA, and 5-HIAA in the Striatum of the Mouse
Caffeine (10 mg/kg) and the adenosine A1 receptor antag-
onist DPCPX at a lower dose (1.25 mg/kg) given alone were
without effect on extracellular level of DA in the mouse
striatum (Fig. 6a). However, the adenosine A2A receptor
antagonist KW 6002 at both doses (1.25 and 2.5 mg/kg) and
the adenosine A1 receptor antagonist DPCPX at a higher
dose of 2.5 mg/kg significantly increased extracellular DA
level (P = 0.0001 and P = 0.001, respectively, Fig. 6a).
Repeated measures ANOVA of these data showed a statis-
tically significant effect of treatment groups [F5,21 = 357,
P = 0], sampling period [F8,168 = 11.2, P = 0], and the
interaction between treatment groups and sampling period
[F40,168 = 5.43, P = 0].
Extracellular serotonin level was not changed by caf-
feine but was increased by higher doses (2.5 mg/kg) of the
adenosine A1 and A2A receptor antagonists, DPCPX and
KW 6002 (Fig. 6b). Repeated measures ANOVA of these
data showed no significant effect of treatment groups
[F5,18 = 19.87, P = 0.0001], sampling period [F8,144 =
8.54, P = 0], and the interaction between treatment groups
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Fig. 5 The effect of adenosine A1 and A2A receptor antagonists,
DPCPX and KW 6002 (KW) on the changes in extracellular level of
DOPAC, HVA, and 5-HIAA induced by MDMA in the mouse
striatum. DPCPX (1.25 and 2.5 mg/kg) and KW (1.25 and 2.5 mg/kg)
were injected simultaneously with MDMA 40 mg/kg as indicated
with an arrow. Values are the mean ± SEM (n = 6–8 animals).
*P \ 0.01–0.0002 represents a significant difference in comparison to
control group; ‘‘a’’ P \ 0.03–0.0003 represents a significant differ-
ence in comparison to MDMA group (repeated measures ANOVA
and Tukey’s post-hoc test)
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The level of the extraneuronal DA metabolite, 3-MT
was not affected by caffeine and adenosine A1 and A2A
receptor antagonists when given alone (Fig. 6c). Repeated
measures ANOVA of these data showed a statistically non-
significant effect of treatment groups [F5,19 = 0.69,
P = 0.64], sampling period [F8,152 = 1.10, P = 0.36], and
the interaction between treatment groups and sampling
period [F40,152 = 1.07, P = 0.37].
The extracellular level of DOPAC was not changed
either by caffeine or the adenosine A1 and A2A receptor
antagonists DPCPX and KW 6002, respectively (Fig. 6d).
Repeated measures ANOVA of these data showed no sig-
nificant effect of treatment groups [F5,19 = 0.60, P = 0.7],
sampling period [F8,152 = 0.66, P = 0.73], and the inter-
action between treatment groups and sampling period
[F40,152 = 0.89, P = 0.66].
Similarly, the final catecholamine metabolite, HVA was
also not affected by caffeine and the adenosine A1 and
A2A receptor antagonists DPCPX and KW 6002, respec-
tively (Fig. 6e). Repeated measures ANOVA of these data
showed no significant effect of treatment groups
[F5,19 = 0.24, P = 0.94], sampling period [F8,152 = 0.58,
P = 0.79], and the interaction between treatment groups
and sampling period [F40,152 = 1.13, P = 0.3].
Caffeine and the adenosine A1 and A2A receptor
antagonists DPCPX and KW 6002 did not influence the
extracellular level of the serotonin metabolite, 5-HIAA
(Fig. 6f). Repeated measures ANOVA of these data
showed no significant effect of treatment groups
[F5,19 = 1.31, P = 0.3], sampling period [F8,152 = 1.89,
P = 0.06], and the interaction between treatment groups



















































































































































































Fig. 6 The effect of caffeine (CAF) and adenosine A1 and A2A
receptor antagonists, DPCPX and KW 6002 (KW) on extracellular
level of DA, 5-HT, 3-MT, DOPAC, HVA, and 5-HIAA in the mouse
striatum. CAF (10 mg/kg), DPCPX (1.25 and 2.5 mg/kg), and KW
(1.25 and 2.5 mg/kg) were injected as indicated with an arrow.
Values are the mean ± SEM (n = 6–8 animals). *P \ 0.05–0.0002
represents a significant difference in comparison to control group
(repeated measures ANOVA and Tukey’s post-hoc test)
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The basal extracellular levels of DA, 5-HT, 3-MT, DOPAC,
HVA, and 5-HIAA (in pg/10 ll, n = 78) were 7.6 ± 0.62,
2.1 ± 0.23, 12.7 ± 1.18, 1493 ± 140, 1632 ± 150, and
388 ± 42, respectively, and no significantdifferences between
experimental groups were observed.
The Effect of Adenosine A1/A2A Receptor Antagonist
CGS 15943A on MDMA-Induced Changes
in Extracellular Level of DA, 5-HT, 3-MT, DOPAC,
HVA, and 5-HIAA in the Striatum of the Mouse
The non-selective A1/A2A adenosine receptor antagonist,
CGS 15943A at a dose of 6 mg/kg but not at the lower one
(3 mg/kg) significantly (P = 0.0002) enhanced the increase
in striatal DA release induced by MDMA (Fig. 7a). Repe-
ated measures ANOVA of these data showed a significant
effect of treatment groups [F5,20 = 155, P = 0], sampling
period [F8,160 = 87, P = 0], and the interaction between
treatment groups and sampling period [F40,160 = 24,
P = 0]. Similarly, CGS 15943A at a higher dose increased
5-HT release (P = 0.0002) produced by MDMA (Fig. 7b).
Repeated measures ANOVA of these data showed a sig-
nificant effect of treatment groups [F5,20 = 156, P = 0],
sampling period [F8,160 = 77, P = 0], and the interaction
between treatment groups and sampling period
[F40,160 = 19, P = 0]. The increase in the extraneuronal DA
metabolite level, 3-MT was enhanced by CGS 15943A at a
dose of 6 mg/kg (Fig. 7c). Repeated measures ANOVA of
these data showed a significant effect of treatment groups
[F5,20 = 173, P = 0], sampling period [F8,160 = 38,
P = 0], and the interaction between treatment groups and
sampling period [F40,160 = 11, P = 0]. The level of the
intraneuronal metabolite of DA, DOPAC decreased by
MDMA was not affected by both doses of CGS 15943A
(Fig. 7d). Repeated measures ANOVA of these data showed
a significant effect of treatment groups [F5,20 = 121,
P = 0], sampling period [F8,160 = 38, P = 0], and the
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Fig. 7 The effect of the adenosine A1/A2A receptor antagonist CGS
15943A (CGS) on MDMA-induced changes in extracellular level of
DA, 5-HT, 3-MT, DOPAC, HVA, and 5-HIAA in the mouse striatum.
CGS 15943A (3 and 6 mg/kg) was injected simultaneously with
MDMA 40 mg/kg as indicated with an arrow. Values are the
mean ± SEM (n = 4 animals). *P \ 0.01–0.0002 represents signif-
icant difference in comparison to control group; ‘‘a’’
P \ 0.02–0.0002 represents a significant difference in comparison
to MDMA group (repeated measures ANOVA and Tukey’s post-hoc
test)
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[F40,160 = 11, P = 0]. The decrease in HVA induced by
MDMA was not affected by CGS 15943A (Fig. 7e). Repe-
ated measures ANOVA of these data showed a significant
effect of treatment groups [F5,20 = 5.92, P = 0.002], sam-
pling period [F8,160 = 12.4, P = 0], and the interaction
between treatment groups and sampling period
[F40,160 = 2.12, P = 0.001]. The serotonin metabolite,
5-HIAA was decreased by MDMA, but its effect was not
changed by CGS 15943A (Fig. 7f). Repeated measures
ANOVA of these data showed a significant effect of treat-
ment groups [F5,20 = 7.06, P = 0.002], sampling period
[F8,160 = 19.6, P = 0], and the interaction between treat-
ment groups and sampling period [F40,160 = 3.68, P = 0].
CGS 15943A given alone did not influence the extracellular
level of DA, 5-HT, 3-MT, DOPAC, HVA, and 5-HIAA in
the mouse striatum (Fig. 7a–f).
The basal extracellular levels of DA, 5-HT, 3-MT,
DOPAC, HVA, and 5-HIAA in this experiment were (in
pg/10 ll, n = 78) 8.14 ± 1.1, 2.41 ± 0.45, 12.65 ± 1.64,
1615 ± 152, 1299 ± 119, and 337 ± 40, respectively. We
did not observe significant differences between experi-
mental groups in the basal levels of neurotransmitters and
their metabolites.
Discussion
The findings of our in vivo study showed that MDMA
increased DA and 5-HT release in a dose-dependent
manner in the mouse striatum. However, the effect of
MDMA on 5-HT release was weaker than that on DA
release which does not correspond to the rank order of
potency for MDMA inhibition of the DA and 5-HT uptake
in vitro, where MDMA exhibited a higher potency at
serotonin transporter (SERT) than at dopamine transporter
(DAT) (Han and Gu 2006). However, it has to be noted that
MDMA has the ability to directly bind to a number of
classical neurotransmitter receptors which may contribute
to a stronger MDMA effect on DA release. For instance,
MDMA by acting directly at brain nicotinic acetylcholine
receptors may increase striatal DA release (Faure et al.
2014). In addition, after acute administration of MDMA,
DA release may be increased by activation of specific 5-HT
receptors. 5-HT2A receptors densely localized on gluta-
matergic cells in the frontal cortex and activated by the
released 5-HT may elicit an increase in glutamate level
leading to a rise in DA release in an indirect way (Alex and
Pehek 2007). Furthermore, MDMA may suppress nigral
GABA release following 5-HT2A/2C receptor activation
thus causing disinhibition of the striatal DA neurons (Gu-
delsky and Yamamoto 2008). The MDMA effect may be
additionally strengthened by its major metabolite, 3,4-
methylenedioxyamphetamine (MDA) having a higher
activity at DAT than at SERT, thereby slightly more
increasing DA release than 5-HT (Baumann et al. 2007).
In our study, caffeine alone at a dose of 10 mg/kg failed
to alter DA and 5-HT release in the mouse striatum.
However, co-administration of caffeine and MDMA had a
stronger effect on DA and 5-HT release than that of
MDMA alone. It was evidenced that caffeine at doses
between 10 and 40 mg/kg increased spontaneous locomo-
tion in mice and rats (Garret and Holtzman 1994; Niko-
dijevic¸ et al. 1993). On the other hand, caffeine has been
reported to increase DA turnover only at high doses in a
manner unrelated to the locomotor stimulation (Morgan
and Vestal 1989). Ikeda et al. (2011) reported enhancement
of DA release in the striatum of anesthetized rats after
concomitant administration of caffeine (20 mg/kg) and
MDMA (10 mg/kg). These data are in line with our find-
ings showing in vivo synergistic interaction between caf-
feine and MDMA in the mouse striatum. The
pharmacokinetic interactions have also to be considered in
the mechanisms mediating the ability of caffeine to pro-
mote MDMA-induced DA release. MDMA and caffeine
are metabolized in rodents by the same enzyme, CYP1A2
(Singh et al. 2009). Thus competitive interactions between
MDMA and caffeine at CYP1A2 may underlie the mech-
anism of caffeine/MDMA interaction in their effect on DA
as well as 5-HT release. However, MDMA-induced DA
and 5-HT release may be also regulated by adenosine
receptors as shown in other studies in which agonists of
adenosine A1 and A2A receptors decreased methamphet-
amine-induced DA release or KCl-evoked DA and gluta-
mate release in the rat striatum (Gołembiowska and
_Zylewska 1997, 1998) and in behavioral studies in which
the adenosine A2A agonist CGS 21680 provided a partial
protection against MDMA-induced deficit in spatial
learning and hippocampal cell death (Kermanian et al.
2012). Caffeine as a non-selective antagonist of adenosine
A1 and A2A receptors with in vitro affinity in lM range
(Fredholm et al. 1999) may increase DA and glutamate in
the striatum via blockade of inhibitory presynaptic adeno-
sine A1 receptors (Borycz et al. 2007; Ciruela et al. 2006;
Okada et al. 1996). Similarly, adenosine A1 receptor
blockade was shown to increase hippocampal 5-HT release
(Okada et al. 1999). A greater response in terms of DA
release was observed in the striatal tissue slices superfused
with MDMA in combination with caffeine than that
obtained following the application of each of the drugs
alone (Vanattou-Saı¨foudine et al. 2011). Our results show
for the first time the effect of the combined treatment of
caffeine and MDMA not only on DA but also on 5-HT
release as measured by an in vivo microdialysis in mice.
We present the evidence that adenosine A1 and A2A
receptors are involved in this effect by showing that the
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selective antagonists of A1 and A2A adenosine receptors,
DPCPX and KW 6002 were able to mimic the effect of
caffeine. Both adenosine receptor antagonists markedly
enhanced MDMA-induced DA and 5-HT release in the
mouse striatum, but the potency of their effect was dif-
ferent. The effect of KW 6002 at a lower dose (1.25 mg/
kg) was similar to the effect of caffeine co-administered
with MDMA 40 mg/kg. However, the effect of a higher
dose of KW 6002 (2.5 mg/kg) was much stronger on either
DA or 5-HT release than that of caffeine co-administered
with MDMA 40 mg/kg. In turn, the effect of the A1
receptor antagonist, DPCPX given at a higher dose
(2.5 mg/kg) with MDMA on DA release was weaker in
comparison to the effect of combined administration of
MDMA with caffeine or a lower dose of KW 6002. Nev-
ertheless, the difference between the group treated with
DPCPX (2.5 mg/kg) jointly with MDMA was significant in
comparison to MDMA alone. A similar tendency was
observed in DPCPX action on 5-HT release. These results
indicate that A2A rather than A1 receptor blockade plays a
greater role in the potentiating MDMA effect on DA and
5-HT release. One can argue that adenosine receptor
antagonists used in this study differ in occupancy of
adenosine receptors. However, both KW 6002 and DPCPX
show affinity for respective adenosine receptors in a low
nM range (Jacobson and Van Rhee 1997; Saki et al. 2013).
In our study, both drugs were used in their active doses as
evidenced by other tests. DPCPX at doses of 1.25–5 mg/kg
increased motility and locomotion in mice (Kuzmin et al.
2006). KW 6002 at doses of 2.5–3 mg/kg increased loco-
motor activity in mice (Aoyama et al. 2000; Yu et al. 2008)
with similar potency to that of caffeine at a dose of 10 mg/
kg. Interestingly, our findings showed that KW 6002 and
DPCPX alone (but not caffeine) increased the basal
extracellular level of DA and 5-HT. These data indicate
that DA and 5-HT nerve terminals are under tonic influence
of adenosine A1 and A2A receptors. The question arises
what mechanism mediates the control of MDMA-induced
DA and 5-HT release in the mouse striatum by adenosine
receptor blockade. It is known that striatal adenosine A1
receptors have presynaptic and postsynaptic location, and
acting as presynaptic heteroreceptors they may modulate
neurotransmitter release from DA or 5-HT terminals (Ferre´
et al. 1997; Vanattou-Saı¨foudine et al. 2011). Striatal
adenosine A2A receptors are mostly postsynaptic and are
highly expressed in striatopallidal GABAergic neurons,
where they antagonistically interact with dopamine D2
receptors (Ferre´ et al. 1997). In addition, they are localized
in striatal glutamatergic terminals where they are involved
in the modulation of glutamate release (Ciruela et al.
2006). The lack of A2A receptors on striatal DA or 5-HT
terminals suggests that the involvement of A2A receptors
in the mechanism of DA or 5-HT release may be secondary
and related to the changes in the activity of striatal output
pathways elicited by A2A postsynaptic receptors, possibly
by their negative interaction with dopamine D2 receptors.
In fact, there is evidence that peripheral but not local
administration of adenosine A2A antagonists increases
extracellular concentration of DA in the striatum of naive
rats (Gołembiowska et al. 2009; Gołembiowska and _Zyle-
wska 1997; Okada et al. 1996). Moreover, behavioral
studies indicate that rather A2A than A1 adenosine
receptors seem to be involved in the effects of caffeine.
Lazarus et al. (2011) using selective gene deletion strate-
gies demonstrated that A2A receptors in the shell region of
the nucleus accumbens were responsible for the effect of
caffeine on wakefulness. Another study using also genetic
knockout models showed that A2A adenosine receptors
were required for psychomotor stimulant effect of caffeine
in mice (Chen et al. 2010).
Primary action of caffeine seems to be exerted through
adenosine A1 and A2A receptors since these receptors bind
caffeine at low concentrations (Fredholm et al. 1999).
However, caffeine at a dose of 6.25 mg/kg which is known
to induce its stimulant motor effects was shown to occupy
66 % of striatal adenosine A2A receptors and further
increase in its dose would lead to 55 % occupancy of
cortical A1 receptors (Yacoubi et al. 2001). It has to be
taken into consideration that caffeine in a dose of 10 mg/kg
used in our study in which it significantly increased
MDMA-induced DA and 5-HT release may also exert its
effect via blockade of adenosine A3 receptor. Caffeine has
a low in vitro affinity for A3 receptor (Fredholm et al.
2001). However, under conditions of nearly maximal
occupancy of A2A and A1 receptors, adenosine A3
receptor may be responsible for caffeine stimulatory action.
A reduction in caffeine-induced stimulation of motor
activity in A3R KO mice corroborates this suggestion
(Bjo¨rklund et al. 2008). In spite of a low density of A3
receptors in the brain (Linden 1994) and their ca. 100 fold
lower affinity for adenosine in comparison to A1 and A2A
receptors (Jacobson and Van Rhee 1997) A3 receptors may
be activated under pathological conditions (e.g., ischemia)
when adenosine concentration is increased (Chen et al.
2006). However, this is not a case in our study since we did
not observe increased adenosine extracellular level after
administration of MDMA into mice (results not shown).
Therefore, rather A1 and A2A but not A3 adenosine
receptors seem to be engaged in the potentiating effect of
caffeine on DA and 5-HT release in the mouse striatum.
Another possibility which may explain the effect of
caffeine and A2A receptor antagonists on DA and 5-HT
release under basal and stimulated conditions is their effect
on metabolism of these monoamines. KW 6002 and
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caffeine represent the class of methylxanthine A2A
antagonists which are competitive monoamine oxidase-B
(MAO-B) inhibitors (Castagnoli et al. 2003). Thus, meth-
ylxanthine A2A antagonists by slowing down cytosolic
monoamine utilization and their conversion to DOPAC or
5-HIAA may increase the synaptic level of DA or 5-HT.
This effect may be particularly important in the presence of
MDMA, thereby increasing the extravesicular monoamine
neurotransmitters inside nerve endings which are mainly
metabolized by MAO (Sprague et al. 1998). In our study,
we observed a decrease in extracellular level of DOPAC,
homovanillic acid (HVA), and 5-hydroxyindoleacetic acid
(5-HIAA) resulting from the inhibition of DAT or SERT by
MDMA. Caffeine or KW 6002 as methylxanthine MAO-B
inhibitors should slow down monoamine transformation
into DOPAC and HVA, thus additionally causing the
decrease in extracellular level of these metabolites. How-
ever, in our study, no differences were found in groups
treated with the combination of MDMA and KW 6002 or
caffeine in comparison to MDMA alone. This may suggest
that the effect on MAO-B inhibition by caffeine or KW
6002 is negligible or it is masked by rapid removal of DA
from cytosolic compartment and its metabolism in the
synaptic cleft. The latter possibility is confirmed by the fact
that KW 6002 which inhibits MAO-B with Ki value in lM
range (Petzer et al. 2003), but not caffeine which inhibits
MAO-B in mM range (Petzer et al. 2013), increased the
extracellular DA level when given alone in mice. Inter-
estingly, KW 6002 and DPCPX reversed to control values
of the extracellular level of 5-HIAA decreased by MDMA.
As serotonin is the substrate for MAO-A isoform (Youdim
et al. 2006), increase in extracellular 5-HIAA level may
rather result from the stimulation of 5-HT synthesis by
these antagonists in the presence of MDMA.
In order to resolve whether the effect of caffeine on
MDMA-induced DA and 5-HT release in the mouse striatum
is mediated via postsynaptic adenosine A2A receptors but
not by MAO inhibition, we tested if the nonxanthine aden-
osine receptor antagonist CGS 15943A lacking MAO-B
activity (Castagnoli et al. 2003) increases, like caffeine and
KW 6002, DA and 5-HT release. CGS 15943A is a potent
adenosine receptor antagonist with seven-fold greater selec-
tivity for A2A receptor versus A1 receptor, and an IC50 of 3
nM at the A2A receptor (Francis et al. 1988). When used in
our study in pharmacologically effective doses (Czuczwar
et al. 1991; Griebel et al. 1991), it enhanced MDMA effect on
DA and 5-HT release. We also did not observe differences in
extracellular level of DOPAC, HVA, and 5-HIAA in groups
treated with MDMA alone and its combination with CGS
15943A. These findings suggest that the caffeine effect on
MDMA-induced DA and 5-HT release in the mouse striatum
is linked to its action on A2A adenosine receptors and is
rather not related to the modification of MAO activity.
Interestingly, co-treatment of MDMA and caffeine or
adenosine receptor antagonists markedly increased extra-
cellular level of 3-methoxytyramine (3-MT), another
metabolite of DA. 3-MT as a product of catabolic enzyme
catechol-O-methyltransferase (EC 2.1.1.6; COMT) activity
is a good indicator of extraneuronal metabolism of DA
released into synaptic cleft. The increase in 3-MT level
induced by caffeine or adenosine receptor antagonists co-
administered with MDMA suggests that these drugs pro-
longed DA clearance from extracellular space resulting in a
greater sustained extraneuronal DA level. These data
strongly indicate that the enhancement of astroglia and
microglia reactivity by caffeine (Khairnar et al. 2010) or
neuroinflammation (Costa et al. 2014) may be due to an
increase in DA release, excessive oxidative stress or for-
mation of serotonergic toxins (Gołembiowska et al. 2009;
Gołembiowska and Dziubina 2012; Schmitt and Reith 2010)
which all lead to neurotoxicity. On the other hand, caffeine
at low doses produces antioxidant effects (Abreu et al. 2011;
Gołembiowska et al. 2008, 2013; Go´rska et al. 2014; Ruiz-
Medina et al. 2013; Sinchai et al. 2011) and reduces neu-
rotoxic effect exerted by various toxins. Therefore, further
studies especially after prolonged exposure to caffeine and
MDMA in animal models are necessary to understand the










Fig. 8 Diagram showing a summary and conclusion of the presented
findings. MDMA by blocking 5-HT transporter (SERT) and DA
transporter (DAT) produces an increase in extracellular level of 5-HT
and DA. Caffeine enhances the effect of MDMA on 5-HT and DA by
blocking mainly adenosine A2A receptors and to a smaller extent
adenosine A1 receptors. There is no evidence for the role of MAO-B
inhibition by caffeine in its effect on monoamine release
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In conclusion, the findings of our study demonstrate that
caffeine exacerbates the MDMA effect on DA and 5-HT
release in the mouse striatum. Its effect is mimicked by
selective antagonists of adenosine A1 and A2A receptors
corroborating the role of these receptors in the caffeine
effect. The summary of our findings is presented in a dia-
gram in Fig. 8. Our neurochemical data may help to
understand the mechanism of MDMA neurotoxicity when
it is used recreationally in combination with other con-
comitants, such as caffeine.
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